ContraFect Corp (NASDAQ:CFRX) shares dropped 2.3% on Monday . The stock traded as low as $0.41 and last traded at $0.42. Approximately 5,286 shares were traded during mid-day trading, a decline of 100% from the average daily volume of 1,106,588 shares. The stock had previously closed at $0.43.

CFRX has been the topic of several research analyst reports. Chardan Capital reissued a “buy” rating and issued a $1.50 price target on shares of ContraFect in a report on Wednesday, May 15th. Maxim Group initiated coverage on shares of ContraFect in a report on Tuesday. They set a “buy” rating on the stock. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. ContraFect currently has a consensus rating of “Buy” and a consensus price target of $1.50.

The firm has a market capitalization of $34.10 million, a P/E ratio of -1.33 and a beta of -0.13. The company has a debt-to-equity ratio of 0.20, a quick ratio of 4.23 and a current ratio of 4.23.

ContraFect (NASDAQ:CFRX) last announced its earnings results on Friday, May 10th. The biotechnology company reported $0.15 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.11) by $0.26. On average, equities analysts predict that ContraFect Corp will post -0.14 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently made changes to their positions in CFRX. Vanguard Group Inc. increased its holdings in shares of ContraFect by 24.2% during the third quarter. Vanguard Group Inc. now owns 2,634,428 shares of the biotechnology company’s stock worth $5,454,000 after purchasing an additional 512,940 shares during the period. Vanguard Group Inc increased its holdings in shares of ContraFect by 24.2% during the third quarter. Vanguard Group Inc now owns 2,634,428 shares of the biotechnology company’s stock worth $5,454,000 after purchasing an additional 512,940 shares during the period. Northern Trust Corp increased its holdings in shares of ContraFect by 46.5% during the fourth quarter. Northern Trust Corp now owns 114,131 shares of the biotechnology company’s stock worth $175,000 after purchasing an additional 36,239 shares during the period. White Pine Capital LLC increased its holdings in shares of ContraFect by 24.9% during the fourth quarter. White Pine Capital LLC now owns 294,730 shares of the biotechnology company’s stock worth $451,000 after purchasing an additional 58,725 shares during the period. Finally, Geode Capital Management LLC increased its holdings in shares of ContraFect by 8.3% during the fourth quarter. Geode Capital Management LLC now owns 377,908 shares of the biotechnology company’s stock worth $578,000 after purchasing an additional 29,009 shares during the period. 37.60% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “ContraFect (NASDAQ:CFRX) Trading Down 2.3%” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://www.thecerbatgem.com/2019/06/12/contrafect-nasdaqcfrx-trading-down-2-3.html.

About ContraFect (NASDAQ:CFRX)

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza.

Featured Article: What is the S&P 500 Index?

Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.